111 related articles for article (PubMed ID: 12899128)
1. [Preclinical evaluation of drug induced QT prolongation].
Hashimoto K
Nihon Yakurigaku Zasshi; 2003 Jun; 121(6):408-10. PubMed ID: 12899128
[No Abstract] [Full Text] [Related]
2. Molecular determinants of high-affinity drug binding to HERG channels.
Mitcheson JS; Perry MD
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):667-74. PubMed ID: 14579516
[TBL] [Abstract][Full Text] [Related]
3. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
[TBL] [Abstract][Full Text] [Related]
4. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management.
Anderson ME; Al-Khatib SM; Roden DM; Califf RM;
Am Heart J; 2002 Nov; 144(5):769-81. PubMed ID: 12422144
[No Abstract] [Full Text] [Related]
5. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
Pearlstein R; Vaz R; Rampe D
J Med Chem; 2003 May; 46(11):2017-22. PubMed ID: 12747773
[No Abstract] [Full Text] [Related]
6. Drug-induced q-T prolongation.
Kao LW; Furbee RB
Med Clin North Am; 2005 Nov; 89(6):1125-44, x. PubMed ID: 16227057
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
Shah RR
Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
[TBL] [Abstract][Full Text] [Related]
8. TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability).
Hondeghem LM
Novartis Found Symp; 2005; 266():235-44; discussion 244-50. PubMed ID: 16050272
[TBL] [Abstract][Full Text] [Related]
9. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
Gintant GA; Su Z; Martin RL; Cox BF
Toxicol Pathol; 2006; 34(1):81-90. PubMed ID: 16507548
[TBL] [Abstract][Full Text] [Related]
10. Droperidol-induced proarrhythmia: the beginning of an answer?
Charbit B; Funck-Brentano C
Anesthesiology; 2007 Oct; 107(4):524-6. PubMed ID: 17893444
[No Abstract] [Full Text] [Related]
11. Blockade of HERG channels by HIV protease inhibitors.
Anson BD; Weaver JG; Ackerman MJ; Akinsete O; Henry K; January CT; Badley AD
Lancet; 2005 Feb 19-25; 365(9460):682-6. PubMed ID: 15721475
[TBL] [Abstract][Full Text] [Related]
12. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced QT prolongation.
Tzivoni D
Isr Med Assoc J; 2001 Jun; 3(6):472. PubMed ID: 11433657
[No Abstract] [Full Text] [Related]
14. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Hancox JC; McPate MJ; El Harchi A; Zhang YH
Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
[TBL] [Abstract][Full Text] [Related]
15. A common antitussive drug, clobutinol, precipitates the long QT syndrome 2.
Bellocq C; Wilders R; Schott JJ; Louérat-Oriou B; Boisseau P; Le Marec H; Escande D; Baró I
Mol Pharmacol; 2004 Nov; 66(5):1093-102. PubMed ID: 15280442
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced prolongation of the QT interval.
Cruciani RA; Portenoy RK; Homel P
N Engl J Med; 2004 Jun; 350(25):2618-21; author reply 2618-21. PubMed ID: 15208786
[No Abstract] [Full Text] [Related]
17. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes.
Webster R; Leishman D; Walker D
Curr Opin Drug Discov Devel; 2002 Jan; 5(1):116-26. PubMed ID: 11865665
[TBL] [Abstract][Full Text] [Related]
18. [Long-QT caused by drugs and torsade de pointes: a genetic basis?].
Schwartz PJ
Cardiologia; 1999 Dec; 44 Suppl 1(Pt 1):277-9. PubMed ID: 12497921
[No Abstract] [Full Text] [Related]
19. Drug-induced prolongation of the QT interval.
Roden DM
N Engl J Med; 2004 Mar; 350(10):1013-22. PubMed ID: 14999113
[No Abstract] [Full Text] [Related]
20. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk.
Wible BA; Hawryluk P; Ficker E; Kuryshev YA; Kirsch G; Brown AM
J Pharmacol Toxicol Methods; 2005; 52(1):136-45. PubMed ID: 15950494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
